You are here: Industry Insights > ADC

News List

Henlius Licenses Phase 3 Innovative HER2 ADC from GeneQuantum Henlius
August 20, 2025
Recently, Shanghai Henlius Biotech, Inc. (2696.HK) has entered into a strategic collaboration with GeneQuantum Healthcare (Suzhou) Co., Ltd. ("GeneQuantum").
InnoCare Releases 2025 Interim Results and Business Highlights PharmaSources
August 20, 2025
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2025 interim results as of 30 June 2025.
Alphamab Oncology Announces Anti-HER2 Biparatopic ADC JSKN003 Obtained Orphan Drug Designation from the U.S. FDA for the Treatment of GC/GEJ PR Newswire
July 29, 2025
Alphamab Oncology announced that anti-HER2 biparatopic antibody-drug conjugate JSKN003 has been granted Orphan Drug Designation by the FDA for the treatment of gastric cancer?and gastroesophageal junction cancer (GC/GEJ).
InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China PharmaSources
July 04, 2025
InnoCare Pharmaannounced the approval of the Investigational New Drug (IND) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct the clinical trial of a novel B7-H3 targeted ADC ICP-B794.
Henlius 2024 Annual Results: Steady Revenue Growth with a Net Profit of RMB820.5 million, Up by 50.3% YoY PR Newswire
March 25, 2025
Henlius reported 2024 results with rising revenue and profit. It advanced in oncology, expanded globally, and made pipeline progress.
Anti-HER2 Biparatopic ADC JSKN003 Has Been Granted Breakthrough-Therapy Designation for the Treatment of PROC PR Newswire
March 18, 2025
Alphamab Oncology and CSPC jointly announced that anti-HER2 biparatopic ADC JSKN003 has been granted Breakthrough Therapy Designation by the CDE of the NMPA.
Alphamab Oncology Announces the Study for Ovarian Cancer PR Newswire
February 13, 2025
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Ovarian Cancer of Anti-HER2 Bispecific ADC JSKN003
Study Results Abstracts From Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan At 2025 ASCO Genitourinary Cancers Symposium PR Newswire
February 13, 2025
Study Results Abstracts From Aac-TMT At 2025 ASCO Genitourinary Cancers Symposium
Samsung Biologics presents business updates at 2025 J.P. Morgan Healthcare Conference PRNewswire
January 15, 2025
Samsung Biologics (KRX: 207940.KS) announced its latest business achievements and 2025 outlook at the 43rd J.P. Morgan Healthcare Conference, which was held in San Francisco between January 13-16.
Samsung Biologics extends collaboration with LigaChem Biosciences for ADC development PRNewswire
January 09, 2025
Samsung Biologics (KRX: 207940.KS) announced to extend collaboration with LigaChem Biosciences (KOSDAQ: 141080) to provide antibody-drug conjugate (ADC) services.